Approval Record: BEXLUTRY — CURIUM, ORIG (Not disclosed in the FDA record.)

Key facts

Regulatory context

This application was reviewed under FDA's ORIG submission pathway. A New Drug Application (NDA) is the FDA pathway used to approve a new drug product, typically requiring the sponsor to submit full preclinical and clinical evidence of safety and efficacy for the intended use, along with manufacturing and labeling information. FDA approval of an application does not itself guarantee ongoing marketing; sponsors remain subject to post-approval manufacturing inspections and adverse-event reporting requirements. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission.

What was approved

FDA's record shows CURIUM as the sponsor of BEXLUTRY, with the generic name recorded as unspecified and dosage form INJECTABLE. A New Drug Application (NDA) is the FDA pathway used to approve a new drug product, typically requiring the sponsor to submit full preclinical and clinical evidence of safety and efficacy for the intended use, along with manufacturing and labeling information. This specific application is submission type ORIG (submission number 1) under application number NDA218525, with a submission status date of 20260914. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. This record is drawn directly from FDA's own approvals database rather than from company press materials. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission.

CURIUM’s FDA history

Argus HQ has recorded 1 total FDA action tied to CURIUM: 0 warning letters, 0 recalls, 1 approval record, and 0 Form 483 inspection citations.

Frequently asked questions

What dosage form is BEXLUTRY?

BEXLUTRY is formulated as: INJECTABLE.

What did FDA approve?

FDA's record shows nda approval for BEXLUTRY (unspecified), dosage form INJECTABLE, sponsored by CURIUM, under application number NDA218525. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission.

What does the submission type mean?

A New Drug Application (NDA) is the FDA pathway used to approve a new drug product, typically requiring the sponsor to submit full preclinical and clinical evidence of safety and efficacy for the intended use, along with manufacturing and labeling information.

Is this product available now?

FDA's record lists a submission status date of 20260914. Availability, pricing, and distribution details beyond the submission status date are Not disclosed in the FDA record. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission.

Related enforcement actions

• Approval (recent): ZYDUS LIFESCIENCES — ANDA approval: TRETINOIN (unspecified) →
• Approval (recent): STRIDES PHARMA — ANDA approval: MILNACIPRAN HYDROCHLORIDE (unspecified) →
• Approval (recent): MACLEODS PHARMS — ANDA approval: MILNACIPRAN HYDROCHLORIDE (unspecified) →
• Approval (recent): EMERGE BIOSCIENCE PTE. LTD. — BLA approval: GARZULYS (unspecified) →
• Approval (recent): ZYDUS LIFESCIENCES — ANDA approval: LETROZOLE (unspecified) →
• Approval (recent): DIFGEN PHARMS — ANDA approval: EPINEPHRINE (unspecified) →
• Approval (recent): AJANTA PHARMA LTD — ANDA approval: HALOPERIDOL (unspecified) →
• Approval (recent): AUROLIFE PHARMA LLC — ANDA approval: BECLOMETHASONE DIPROPIONATE (unspecified) →